11 November 2025 : Original article
Invasive Coronary Physiology Assessment for Detecting Microcirculatory Dysfunction in Heart Transplant Recipients
Mateusz Sokolski
ABCDEFG 1,2*, Natalia Oliwia Bernacka CDEF 3, Wiktoria Zychla CDEF 3, Magdalena J. Cielecka BE 1,2, Mateusz Rakowski BE 2,4, Maciej Bochenek BE 1,2, Wiktor Kuliczkowski BE 2,5, Roman Przybylski BEG 2,6, Michał Zakliczyński ABEG 1,2
DOI: 10.12659/AOT.950138
Ann Transplant 2025; 30:e950138
Table 3 Laboratory test results, treatment during study, and other clinical information on patients with normal and abnormal microcirculation.
| Parameter | Coronary microvascular dysfunction | Normal coronary microcirculation | All (n=33) | P |
|---|---|---|---|---|
| Laboratory test results | ||||
| Hgb (g/dL) | 13.25 (2) | 13.17 (2) | 13.19 (2) | 0.916 |
| WBC (thous./uL) | 7.20 (2) | 7.13 (2) | 7.15 (2) | 0.931 |
| Creatinine (mg/dL) | 1.17 [1–1.3] | 1.13 [1.1–1.4] | 1.13 [1.1–1.3] | 0.737 |
| GFR (mL/min/m) | 68.38 (20) | 62.56 (19) | 63.97 (19) | 0.467 |
| Troponin (normal <15.6 ng/L) | 3.5 [1.9–5] | 3.70 [1.9–6.9] | 3.60 [1.9–5.6] | 0.443 |
| NTproBNP (normal <125 pg/mL) | 489.70 [164–545] | 339.00 [227–605] | 342.55 [221–575] | 0.963 |
| Total cholesterol (mg/dL) | 153.52 (58) | 155.66 (29) | 155.12 (38) | 0.892 |
| LDL (mg/dL) | 88.90 (47) | 80.01 (22) | 82.23 (30) | 0.471 |
| HDL (mg/dL) | 48.04 (14) | 50.73 (13) | 50.05 (13) | 0.625 |
| Triglycerides (mg/dL) | 76.17 [65–96] | 114.00 [77–158] | 103.1 [71–136] | 0.048 |
| Fasting glucose (mg/dL) | 102.00 [93–118] | 110.00 [98–132] | 106.00 [98–128] | 0.377 |
| HbA1C (%) | 5.80 [5.3–6.4] | 5.80 [5.6–6.3] | 5.80 [5.5–6.4] | 0.860 |
| Treatment during study | ||||
| Tacrolimus | 7 (88%) | 20 (80%) | 27 (82%) | 0.632 |
| mTOR inhibitor (everolimus/sirolimus) | 0 | 1 (4%) | 1 (3%) | 0.566 |
| Mycophenolate mofetil | 6 (75%) | 20 (80%) | 26 (79%) | 0.763 |
| Cyclosporine | 1 (13%) | 4 (16%) | 5 (15%) | 0.810 |
| Statin | 6 (75%) | 22 (88%) | 28 (85%) | 0.372 |
| Acetylsalicylic acid | 6 (75%) | 21 (84%) | 27 (82%) | 0.566 |
| P2Y12 inhibitor | 0 | 1 (4%) | 1 (3%) | 0.566 |
| Other Information | ||||
| Non-ischemic etiology of heart failure | 2 (25%) | 5 (20%) | 7 (21%) | 0.763 |
| Arterial hypertension | 5 (63%) | 16 (64%) | 21 (64%) | 0.939 |
| Hyperlipidemia | 4 (50%) | 11 (44%) | 15 (45%) | 0.767 |
| Diabetes mellitus | 4 (50%) | 7 (28%) | 11 (33%) | 0.251 |
| Chronic kidney disease | 4 (50%) | 10 (40%) | 14 (42%) | 0.778 |
| Anemia | 3 (38%) | 9 (36%) | 12 (36%) | 0.939 |
| Hyperthyroidism | 1 (13%) | 1 (4%) | 2 (6%) | 0.380 |
| Stroke | 1 (13%) | 6 (24%) | 7 (21%) | 0.489 |
| Nicotine use: past | 1 (13%) | 7 (28%) | 8 (24%) | 0.243 |
| Nicotine use: current | 0 | 4 (16%) | 4 (12%) | |
| Categorical variables are presented as numbers with (%). Continuous variables with a normal distribution are shown as mean (SD). Nonparametric variables are presented as the median with upper and lower quartile. Hgb – hemoglobin; WBC – white blood cells; GFR – glomerular filtration rate; NTproBNP – N-terminal prohormone of brain natriuretic peptide; LDL – low-density lipoprotein; HDL – high-density lipoprotein; HbA1C – glycated hemoglobin. | ||||